Vibrating at up to 30,000 times per second, the sonographic device helps tissue to detach more easily without inflicting a large puncture wound to collect an adequate amount of tissue.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Agentic large-language models can draft hospital discharge summaries that are safe, useful and demonstrably effective at helping to curb physician burnout, according to research conducted at Stanford University.
Heparin-induced thrombocytopenia after heart surgery is a major concern, but prior guidelines were developed without much feedback from actual cardiac surgeons.
Medline already had to recall millions of syringes due to a significant safety risk. Now, multiple procedure kits that include the devices are also being recalled. The issue has been associated with four serious injuries.
“Dr. Saphier would be a catastrophic mistake on messaging and communicating with MAHA at a time where the coalition is very fragile,” one opponent says.
KLAS Research announced the winners of its 2025 Best in KLAS awards this week, recognizing top performers across approximately 150 health informatics market segments.
Payers have reportedly used artificial intelligence algorithms to deny routine requests for PET imaging, instead steering patients to CCTA in some cases.
A California appeals court recently ruled in favor of on-call radiologist Peymam Kangavari, MD, after he was accused of overlooking a bowel obstruction on X-ray and ultrasound images.
Vibrating at up to 30,000 times per second, the sonographic device helps tissue to detach more easily without inflicting a large puncture wound to collect an adequate amount of tissue.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
